|
Group of inventions relates to the application of a hydrocortisone derivative of formula (I) |
|
Carbon sorbent having antibacterial and antimycotic properties and method for production thereof Method of producing a carbon sorbent with antibacterial and antimycotic properties includes impregnating granules of a carbon hemosorbent with 10-50% aqueous solution of glycolic acid for 7-9 hours at room temperature. The ratio of the hemosorbent to the modifier solution of glycolic acid is 1:1. Further, drying is carried out for an hour at 100-110°C. Polycondensation of glycolic acid on the carbon hemosorbent is carried out in two steps: at 185-205°C for 1 hour, at 215-235°C for not less than 5 hours, on a sand bath. The disclosed modified carbon sorbent with antibacterial and antimycotic properties is granules with a round shape, contains not less than 5% polyglycolide, characterised by a specific adsorption surface area of less than 250 m2/g and total pore volume of less than 0.50 cm3/g. |
|
Invention refers to medicine, namely to pharmacy, and concerns developing medical dental pencils containing calcium gluconate, and can be used in integrated treatment of the oral diseases related to calcium deficiency. The dental pencil contains a mechanically active amorphous or amorphous crystalline calcium salt of gluconic acid as an active substance, contains paraffin, Vaseline oil, Tween 80, low-molecular polyethylene (LMPE), Lutrol 127 in the following proportions, g per 1 pencil, taken as a base: mechanically active amorphous or amorphous crystalline calcium salt of gluconic acid - 0.4; paraffin - 0.4, Vaseline oil 0.4, Tween 80 - 0.6, -molecular polyethylene (LMPE) - 2.0, Lutrol 127 - 0.02. As a preserving agent, the dental pencil additionally contains benzoic acid - 0.0008 g. |
|
|
Declared products are presented in the form of suppositories and contain a mechanically active amorphous or amorphocrystalline calcium gluconate as an active substance and additives as a base. One of the declared agents contains hard fat, paraffin, cacao butter and Lutrol F68 as a base in specific proportions. The other agent contains Witepsol W35, Witepsol H15, kollidon CL and Cremophore RH-40 as a base in specific proportions. |
|
|
Invention refers to pharmaceutical industry, namely to an immunomodulator. An immunomodulator for the immunocorrection accompanying the integrated treatment of chronic non-specific pulmonary diseases, chronic obstructive pulmonary disease, bronchial obstruction syndrome, chronic bronchial pneumonia, pulmonary fibrosis, tracheobronchitis, chronic laryngitis, pulmonary, tracheal and pharyngeal cancer; the immunomodulator is prepared by mixing a water infusion of rose bay leaves and a water infusion of yellow melilot taken in equal proportions, with a cattle lung and larynx powder, settling the prepared mixture, keeping on a boiling water bath, cooling; further, the mixture is filtered; the prepared solution is added with cattle blood serum containing leukaemia oncovirus antibodies, hemlock infusion, ascorbic and sorbic acids until all the ingredients fully dissolved; the prepared solution is placed in the water bath, cooled, filtered, sterilised under certain conditions. |
|
|
Invention refers to chemical-pharmaceutical industry, and represents an immunomodulator for treating chronic hepatitis, hepatic cancer, lymphatic sarcoma, chronic leukemia, and for improving the functions of liver and blood-forming organs, for enhancing the immunobiological body characteristics, prepared by mixing 1000 ml of an aqueous infusion of sandy everlasting blossom, pepper mint herb and chicory herb with 50 ml of bovine serum containing leukaemia oncovirus antibodies, 20 ml of wild rosemary infusion, 40 g of ascorbic acid, 2 g of sorbic acid, 0.2 g of folic acid until the ingredients are dissolved completely, with adding 60 g of liver powder, 30 g of lymphatic node powder, 30 g of young bovine spleen powder; the prepared solution is settled at room temperature for 24 hours, then kept at a boiling water bath for 30 minutes and cooled for 6-8 hours at room temperature; the settled solution is filtered, wherein the aqueous herbal solution is prepared by mixing equal proportions of the separately prepared aqueous infusions of 40 g of pepper mint herb in 1000 ml of water, 30 g of sandy everlasting blossom in 1000 ml of water and 30 g of chicory herb in 1000 ml of water, while the wild rosemary infusion is prepared by infusing 60 g of ground wild rosemary blossom in 1000 ml of 70% purified ethanol. |
|
|
Preparing storage-stable suspension of vital helminth eggs Invention refers to pharmaceutical industry, namely to a method for preparing a pharmaceutical preparation for treating inflammatory intestinal diseases. The method for preparing a pharmaceutical preparation for oral administration for inflammatory intestinal diseases, particularly chronic inflammatory gastrointestinal diseases containing a storage-stable suspension of vital eggs of the parasitic, non-pathogenic to humans helminthes Trichuris suis, which involves preparing the suspension of helminth eggs in an acid at pH max. 2 at the first stage; at the following stage, the pH value is increased to min. 4, and a pharmacologically acceptable preserving agent is added. A pharmaceutical preparation for oral administration for inflammatory intestinal diseases, particularly chronic inflammatory intestinal diseases. The use of the pharmaceutical preparation for oral administration for inflammatory alimentary diseases, particularly chronic inflammatory alimentary diseases. |
|
|
Stable water solution of calcium gluconate for injections Claimed invention relates to pharmaceutical industry, namely to stable water calcium gluconate solution for injections. Said stable water calcium gluconate solution for injections contains 0.5-1 wt % of succinic acid as stabiliser, content of calcium gluconate constituting 10 wt %. |
|
|
Composition possessing analgesic, anti-inflammatory and locomotor function improving action Invention refers to a composition possessing analgesic, anti-inflammatory and locomotor function improving action. The composition contains 1-20 wt % of glucosamine sulphate, 1-10 wt % of chondroitin sulphate, 0.0001-10 wt % of methylsulphonylmethane, 0.01-5 wt % of L-proline, ascorbic acid, magnesium. The declared composition additionally contains zinc gluconate, citric acid, a sweetening agent, a flavour, a preserving agent and water. |
|
|
Method for making preparation intensifying alcohol and oxidation product metabolism Invention refers to pharmaceutical industry, particularly a method for making a preparation intensifying alcohol and oxidation product metabolism. The method for making a preparation intensifying alcohol and oxidation product metabolism wherein alcohol dehydrogenase and aldehyde dehydrogenase are immobilised in an agarose solution in the presence of oxidised nicotinamide dinucleotide, reduced nicotinamide dinucleotide, mixed with aqueous extracts of hare's-ear, ginger, rose hip and distilled water in the specific proportions. |
|
|
Invention relates to field of dermatology and represents colloidal solution suitable for dermal and/or local application on skin, as base for compositions of dispersed foam, containing, at least, one active ingredient, at least, one membrane-forming molecule, at least, one foam-generating component and, at least, one solvent, with active ingredient representing dexpanthenol, membrane-forming molecule represents phosphatidylcholine and foam-generating component being selected from opiate, cocoamphoceate, capryl/capramidopropyl betaine, mixture of PEG-5 lauryl citrate/sulfosuccinate/laureatesulfate, mixture of lauryl glucose carboxylate/lauryl glucoside or their mixture. |
|
|
Invention relates to a disinfectant used on hands and skin. The disinfectant contains (a), (b), (c), (d) and (e), but no other microbiocidal disinfecting agents meant for microbiocidal disinfection: (a) 40-90% ethanol, isopropyl alcohol or mixture thereof; (b) lactic acid in amount of 0.1-2% relative the entire weight of the disinfectant; (c) citric acid in amount of 0.01-2% relative the entire weight of the disinfectant; (d) zinc-containing compound which frees a zinc ion in a solution, in amount of 0.001-0.1% relative the entire weight of the disinfectant; (e) one or more pharmaceutically acceptable carriers for supplementing to 100% of the weight of the entire disinfectant. |
|
Claimed is application of beta-hydroxybutyrate or its salts in combination with other active substance or combination of active substances, selected from group, given in the invention formula, for preparation of medication, which possesses cytoprotective activity, including neuroprotective, cardioprotective, anti-ischemic, antihypoxic, antistress and adaptogenic activities, medication and method of prevention, relief and treatment by means of said medication. Demonstrated is synergic of medication components as cytoprotector in urgent states as it possesses complex impact on key links of pathogenesis of said diseases. |
|
Invention relates to medicine, and namely to obstetrics and gynecology, and can be applied for induction of childbirth. For this purpose per orally mifepristone is taken on first day in dose 200 mg three times after every 4 hours. One day after first intake of mifepristone in back fornix of vagina introduced is dinoproston 1 mg. |
|
|
Suppositories for treating proctologic and gynecologic diseases Invention refers to suppositories for treating proctologic and gynaecologic diseases. Said suppositories contain a drug in the form of the dehydrated preparation 'Baliz' or a power-predried form of the preparation 'Baliz', or an active substance pre-recovered from the preparation 'Baliz' in the form of comenic acid or its salts, and also a base representing fatty substances, and a food or medicinal emulsifier. |
|
|
Novel floroglucin derivatives, possessing activity with respect to selectin ligand Claimed invention relates to chemical-pharmaceutical industry. Pharmaceutical compositions including, at least, one compound of formula where -X- represents, for instance, group of formula and Y represents, for instance, group of formula or its pharmaceutically acceptable salts, esters or amides, or pro-drugs and pharmaceutically acceptable carrier, which is acceptable in therapy, can be applied for modulation in vitro and in vivo processes of binding, mediated by binding of E-, P- or L- selectin. |
|
Invention relates to field of medicine, namely to chemical-pharmaceutical industry and, can be applied for treatment of local purulent diseases of soft tissues. In accordance with invention, as active substance, it contains mixture of calcium lactogluconate, calcium carbonate, sodium bicarbonate, benzocaine and saccharose with following component ratio, wt %: Calcium lactogluconate 16.0-65.0; Calcium carbonate 2.0-13.0; Sodium bicarbonate 1.0-3.0; Benzocaine 0.1-13.0; saccharose to 100.0. Method of clamed substance obtaining, consists in preliminary milling and grinding of upper said components and after that, mixing of milled components in proper upper said proportions until homogeneous powder is obtained. |
|
|
Catheter lock solution containing citrate and paraben Invention refers to an aqueous catheter lock solution which contains citrate, photochemical oxidant methylene blue and dispersed or dissolved paraben. The invention refers also to a catheter locking kit and an infusion device containing the aqueous catheter lock solution, and also to a method of prevention or delay of blocking or contamination of a permanent catheter. |
|
Method of treating salivolithiasis Invention refers to medicine, particularly to dentistry, and can be used for treating salivolithiasis. Calculus is destroyed by 7-10 introductions of 0.5-1.0 ml of 2% citric acid in the salivary duct and parenchyma once a day for 30 days; it is combined with supplementary administration of aspirin 0.5 3 times a day, canefron 50 drops 3 times day and knot grass tea 50 ml 3 times a day. One course is required to eliminate the calculus 0.5 cm. The therapeutic course is performed again 120 and 180 days later for treating the greater calculus. |
|
|
Method for excision of residual concrements in patients who sustained surgical procedure Invention is related to medicine, in particular to urology, and is related to removal of residual concrements in patients who sustained surgical procedure. For this purpose patients who sustained surgical procedure receive irrigation of kidney cavities with litholytical solution, which contains ampicillin in amount of 0.1 - 0.3 wt % and complexon in amount of 4-5 wt %. As complexon they use either trilon B or sodium citrate or their mixture with content of each in the mixture of 2-2.5 wt %. Irrigation is carried out at solution temperature of 36.8-37.2°C and constant speed of litholytical solution feed, which is selected within the limits of 1-10 ml/min. |
|
|
Invention refers to medicine, particularly to gastroenterology, and concerns clinical nutrition of the patients with chronic hepatitis C and being on integrated antiviral therapy. The therapy involves introduction of pegylated a-interferon with Ribavirin during 24-28 weeks. The clinical nutrition (CN) enables shift of pH tissues and biological fluids to alkaline and is implemented for one month prior to the beginning of medicinal therapy, therewith and six months thereafter. The CN implies consumption of great amount of potable water - up to 3-4 litres a day, deprivation of "oxidising" products, salt and pickled food. The CN implies consumption of diluted acetic acid and containing products. Herewith 0.25% aqueous solution of sodium citrate is introduced orally daily in a dose 100 ml per an hour. Introduction is repeated throughout 10 hours. Every two week of specified CN, a 7-day break is prescribed. |
|
|
Crystalline calcium salt of gluconic acid or its compound with excipients is processed in grinding activator devices, or to a value of supplied specific energy of not more than 10.4 kJ/g and achieving amorphous-crystalline state, or to a value of specific energy of not less than 10.5 kJ/g and achieving amorphous state. The obtained substances are analysed using X-ray diffraction, infrared, NMR, EPR spectroscopy, mass- and chromatography-mass spectrometry and differential thermal analysis. |
|
Invention refers to pharmaceutics and concerns an agent to treat and prevent the cerebrovascular diseases, containing lithium salt wherein lithium cation is bound with organic acid chosen from the group: adipate, aspartate, benzoate, hammalinolenate, glycinate, gluconate, nicotinate, orotate, salicylate, citrate, and the method for treating said diseases. |
|
|
Present group of inventions relates to medicine, more specifically to ophthalmology and treatment of pathological processes in the cornea. For this purpose pharmaceutical compositions are locally used, containing one active component in form of urea or urea derivative, and a second active component in form of a compound, chosen from a group consisting of citric acid, dibasic potassium phosphate, isopropyl alcohol, sorbite, propylene glycol, polyethyleneglycol, block-polymer polyatomic alcohol and antimetabolites, in sufficient quantities with pH between 4.0 and 8.0. |
|
|
New agent is characterised with antiwithdrawal action, containing L-serine and fructose as an active components and additionally tianin, at mass ratio of L-serine, tianin and fructose (12-18):(0.8-1.2):(40-60) respectively. It is preferentially to use L-tianin at mass ratio of L-serine, L-tianin and fructose as 15:1:50. Said agent can be used as the biological food additive. The invention also concerns a pharmaceutical composition, method of producing and a medical product based on the agent or pharmaceutical composition as tablets, capsules or injections in pharmaceutically acceptable package. The agent allows relieving the alcohol withdrawal caused by overuse, e.g. of products containing ethyl alcohol. |
|
Compounds for metabolic disorder treatment Invention refers to medicine and pharmaceutics and concerns applications of biologically active agent of formula (1) to prepare a medicinal agent for treatment of the condition chosen from the group including insulin unresponsiveness syndrome, diabetes, hyperlipidemia, hypertensia, nephropathy, neuropathy, retinopathy, feet ulceration or diabetes associated cataracts, method of mammal treatment, pharmaceutical composition and biologically active agent containing compound of formula (1). |
|
Antineoplastic preparation which coordination compound on the magnesium gluconate base wherein the ligands are chosen from the group consisting of γ-aminobutyric acid (GABA), 3-hydroxy-GABA, ethylendiaminotetraacetic acid and ethylenglycoltetraacetic acid or binary salt chosen from the group consisting of magnesium butyrogluconate, oxymagnesium butyrogluconate, magnesium glucarate-gluconate, calcium butyrogluconate, calcium oxybutyrogluconate, calcium glucarate-gluconate and their combinations. |
|
|
Agent with immunopotentiating activity Application of D-glucoronic acid as agent with ability to stimulate Th1-dependent type of immune response. |
|
Intensifying of alcohol metabolism Specified acid strengthens an alcohol metabolism and by that prevents adverse consequences from the alcohol use. D-glyceric acid enter simultaneously with alcohol to accelerate elimination of alcohol from an organism. The D-glyceric acid turns in D-glyceride and then to Glycerinum in reactions, catalysed by NADH-aldehyde dehydrogenase complexes which are produced much during ethanol oxidation in the cells of alcohol-metabolising tissues. In these reactions NADH-complexes become NADH-aldehyde dehydrogenased and NADH-alcohol dehydrogenased. These complexes in turn accelerate oxidation of ethanol which occurs in parallel due to intensifying of oxidation of an acetaldehyde to metabolically harmless acetic acid. |
|
Rectal suppositories "baliz" for proctological disease treatment Rectal suppositories contain "Baliz" composition and base, representing mix of confectionery fat, deep-fry fat, and "Epol" emulsifier in proportion 13:11:1 respectively; the components proportion being as follows, in wt %: "Baliz" - 10 to 45, base - the rest. |
|
|
Method for obtaining stable calcium gluconat solution for injections Method consists in additing water-soluble salt of calcium to the solution of calcium gluconat representing calcium Sodium lactatum, a mass ratio of calcium gluconat : calcium Sodium lactatum 10 : (1-3). Mixing of the said components is carried out at heating to 80°C. |
|
|
Medicinal agent for cancer prevention Invention concerns new medicinal agent for cancer prevention representing combination of anticancerogenic agents: antioxidative vitamin retinol acetate (90-270 mg%) and α-tocopherol acetate (1.3-4 g%), antioxidative microelement sodium selenite (1.3-4 mcg%) and calcium gluconate (4-12 g%). |
|
Aqueous injection solution of lhrh antagonist and method for its preparing Invention describes an aqueous injection solution of antagonist of releasing-hormone luteinizing hormone (LHRH) containing gluconic acid, a filling agent and, optionally, a surfactant. LHRH antagonist is chosen from group of substances: cetrorelix, teverelix, D-63153 (Ac-D-Nal-pCl-Z-Phe-3-D-Pal-Ser-N-Me-Tyr-D-H-Cit-Nle-Arg-Pro-D-Ala-NH2), ganipelix, abarelix, antide or azalin B wherein gluconic acid is taken as delta-lactone in the above equimolar amount with respect to the amount of LHRH antagonist, and mannitol is used a filling agent. LHRG antagonist shows significantly improved solubility and can be prepared in higher concentrations and enhanced bioavailability. Also, tendency of LHRH antagonist to aggregation is reduced significantly. |
|
|
Medicinal agent showing multifactor neuroprotective and nootropic effect in cranial trauma Invention proposes using the known anticonvulsant drug acediprolum (other names of substance - depakin, convulex, sodium valproate) as an agent showing the prophylactic hypoxic and mnemasthenia in acute period of cranial trauma. High protective anticonvulsant index is found firstly in sodium valproate in post-traumatic period in large convulsion attacks in case of its prescription since 2 days after trauma. The course using the preparation both recovers the learning rate of traumatized animals up to the normal levels and stimulates acquiring behavioral adaptive responses being among them reproduction of adaptive responses (method for evaluation of mnemasthenic functions). |
|
Disclosed is A-naphthylacetic acid and sodium, potassium and lithium salts thereof having immunomodulatory (based on leukocyte levels in patient blood suffering from viral infection), anti-inflammation (based on normalizing of erythrocyte sedimentation rate and monocytes in patient blood) and anti-tumor properties (in patient suffering from lymphomatoid granulomatosis and carcinoma of lung). Said salts are produced by treatment of A-naphthylacetic acid with solution of NaOH, or KOH, or LiOH, addition of heated distilled water in obtained solution, keeping at the same temperature to produce bright solution, followed by cooling and drying. |
|
Invention proposes an agent belonging to class of nonsteroid anti-inflammatory preparations, namely, associate comprising 2[(2,6-dichlorophenyl)amino]-benzene acetic acid, inosine and N-methylglucosamine. In oral administration this associate inhibits effectively origination and development of malignant and benign tumors of brain, spinal cord, kidneys, breast, esophagus, forestomach, uterus cervix and vagina induced by chemical carcinogens in laboratory animals. Invention provides preparing the preparation possessing the more expressed anti-carcinogenic activity and lesser toxic ulcerous effect. |
|
Method for obtaining 10%-calcium gluconate solution for injections The present innovation deals with the technique to prepare 10%-calcium gluconate solution for injections including dissolving the substance, filtration, pouring and sterilizing; moreover, the substance should be pre-mixed at about 10-30° C with aqueous solution of hydrogen peroxide at concentration ranged 0.00015-0.15% to be kept for about 4-24 h; the mixture should be dissolved in water at 70-90° C to be heated up to 100 C, not more and kept at pressure (0.5±0.02) MPa for 20 min, not less, then solution should be poured into the ampoules and sterilized with flowing steam at 100 C, not more for 1 h, not more. The innovation enables to obtain a stable and noncaramelizing and noncrystalizing solution of calcium gluconate. |
|
|
Strain of bacterium gluconobacter oxydans-03 as producer of baliz and method for preparing baliz Method involves using the strain of microorganism Gluconobacter oxydans-03. Inoculating material is added in the amount 0.75% by volume of fermentation medium. Amount of yeast autolyzate added to fermentation medium is 1.5-2%. Submerged fermentation is carried out for 30-36 h and cultural fluid is separated from bacterial cells with bentonite taken in the amount 0.6% of the cultural liquid volume. The proposed strain possesses the enhanced oxidizing activity and its using as producer of baliz promotes to reducing fermentation period by 2.4-fold. |
|
Method of simulating erosion of solid dental tissues To simulate erosion of solid dental tissues extracted human teeth are immersed for 60 days into white dry wine while adding citric acid to pH 3.5. Such implementation of the method ensures development of erosion 2 mm deep, which is necessary for further working out of treatment methods. |
|
|
Method for preventing post-injection necrosis The present innovation deals with preventing post-injection necrosis of soft tissues as a result of false subcutaneous injection of 10%-calcium chloride solution. One should detect the volume of the introduced 10%-calcium chloride solution; then it is necessary to introduce 5-fold volume of 5%-sodium citrate solution against the volume of calcium chloride injected; then one should apply a sac with ice onto the site of injection for the period of 30 min, not less. The innovation suggested enables to inhibit the processes for tissue damage due to binding calcium cations with anions of sodium citrate along transforming soluble calcium salt into insoluble one to stop calcium transport into the cells and, thus, prevents its damaging action. |
|
|
One should prescribe a curative complex including calcium pantothenate per 0.1 g thrice daily and balneotherapy with carbonate low-mineralized hydrocarbonate magnesium-sodium-calcium-iron water for inner intake per 200 ml thrice daily 30 min before meals, during 3 wk. The present innovation enables to normalize respiratory ventilation capacity and decrease renal risk due to normalizing phosphorus-calcium exchange and higher content of renewed glutathione that is provided due to synergistic action of calcium pantothenate and mineral water. |
|
Claimed agent represents aqueous solution, containing 2-150 g of zinc polyacrylate, 10-100 g sodium alginate and 1-30 of acetic acid in 1 l of distilled water. Agent of present invention being in contact with blood and tissues provides film formation 30 s. |
|
|
Method for separating afterbirth and prophylaxis of postnatal endometritis in cows Method involves intramuscular administration of oxytocin in the dose 25-60 U in combination with 8% sodium chloride solution in volume up to 2.0 l containing medicinal substances in the following ratio of components: potassium iodide, 2.0 g - 7.7%; furacillin, 0.5 g - 1.9%; metronidazol, 2.0 g - 7.7%; analgin, 0.5 g - 1.9%; sodium hydrocarbonate, 9.0 g - 34.6%; potato starch, 5.0 g - 19.3%; citric acid, 7.0 g - 26.9%. Invention promotes to dehydration and decreasing volume of afterbirth villi cotyledons resulting to loss of their bind with uterus caruncle crypts and get out from them that, in turn, promotes to expulsion of afterbirth from the uterus cavity totally. Invention can be used for separation of afterbirth and prophylaxis of postnatal endometritis in cows. |
|
Invention relates to hemostatic glue. Glue comprises an aqueous solution containing 20-150 g of polyacrylate zinc, 1-30 ml of acetic acid and 1-100 g of cellulose in 1 l of distilled water. Glue shows capacity to stop bleedings and to glue tissues. Invention provides stopping bleeding and formation of film in contact with blood and tissues for 60 s. |
|
|
Invention relates to hemostatic glue. Hemostatic glue represents an aqueous solution containing 10-100 g of cellulose, 1-30 ml of acetic acid and 1-150 g of feracryl in 1 l of distilled water. Invention provides cessation of bleeding and film formation in contact of this glue with blood and tissues for 30 s. |
|
|
Method for treating patients with acute inflammatory diseases of uterine adnexa One should perform laparoscopy, drain purulent foci, remove destructive tissues and wash abdominal cavity with great amount of "Baliz-2" introduced into abdominal cavity by fractional portions per 1-1.5 l at exposure up to 3 min either once or up to three times. The method provides complex impact as antibacterial, antioxidant and immunocorrecting actions of the preparation in area of lesion and, thus, quick interruption of acute stage by preventing the development of adhesions and saving reproductive function in this category of patients. |
|
|
After performing operative interference and sanitation of patient's abdominal cavity the latter should be introduced with sterile phosphate-citrate buffer solution at pH being5.6 at the quantity of 1 l to be applied for washing the organs of abdominal cavity. Then its greater part should be removed by keeping up to 200 ml solution in abdominal cavity. The present innovation enables to activate thrombin being a constituent of an exudates in abdominal cavity and inhibits the development of adhesion's primary component - fibrin. |
|
|
Method for correcting microcirculatory disorders in patients with thermal trauma During the first 2 d since the moment of trauma one should intravenously inject infusion solution of vasaprostan additionally to conventional anti-shock therapy at 1 mcg/kg patient's body weight daily. The present innovation favors to normalize capillary walls' tonicity, decrease their permeability and improve the values of blood hemoconcentration and viscosity. |
Another patent 2551094.